Quality Evaluation of Clinical Practice Guidelines for Central Precocious Puberty
10.13748/j.cnki.issn1007-7693.20223176
- VernacularTitle:中枢性性早熟临床实践指南的质量评价
- Author:
Weiwei ZHENG
1
;
Bin ZHENG
1
;
Maobai LIU
1
Author Information
1. Fujian Medical University Union Hospital, Fuzhou 350001, China
- Publication Type:Journal Article
- Keywords:
central precocious puberty ； guidelines ；AGREE II； quality evaluation
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(1):119-125
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To understand the status of clinical practice guidelines and consensus on central precocious puberty, evaluate and analyze its quality, and to provide reference for the revision and improvement of clinical decision-making and consensus on central precocious puberty.
METHODS
PubMed, OVID, CNKI, Wanfang database, International Guideline Alliance, Guidelines International Network(GIN), National Institute for Health and Care Excellence(NICE), Scottish Intercollegiate Guidelines Network(SIGN), American Society of Clinical Oncology(ASCO), American Urological Association(AUA) and other Chinese and English databases and related websites were searched with computer. The retrieval time was from the establishment of the database to May 2021. Two researchers rigorously screened the literature according to inclusion and exclusion criteria, and included clinical practice guidelines. The Appraisal of Guidelines for Research & Evaluation II(AGREE II) was used to evaluate and analyze the quality, and the recommendations for drug therapy were compared and summarized.
RESULTS
Five guidelines were included in this study. The quality evaluation results of AGREE II showed that the average standardization scores of the six fields were 86.6% for scope and purpose, 43.9% for participants, 22.3% for rigor, 75.5% for clarity, 40.0% for application, and 40.8% for independence. Four guidelines were recommended for grade B and one was recommended for grade C.
CONCLUSION
The overall methodological quality of clinical practice guidelines for central precocious puberty is moderately to low. High-quality evidence-based clinical practice guidelines for central precocious puberty should be developed strictly in accordance with the formulation standards of evidence-based guidelines and the requirements of each domain of AGREE II.
